The cerebral cortical cup technique has been used to study the effects of nifedipine and felodipine on adenosine and inosine release from the rat brain. After basal and hypoxia (8% 0 2 )-evoked control levels of purine release had been established, these 1,4-dihydro pyridine calcium antagonists were administered intraperi toneally (1 mg/kg). Both agents depressed basal levels of purine efflux and suppressed the hypoxia-evoked release Winn HR, Welsh JE, Ru bio R, Berne RM (l980b) Brain adeno brain adenosine during bicuculline-induced seizures in rats. Effects of hypoxia and altered blood pressure. Circ Res 47:568-577 Winn RH , Welsh JE, Ru bio R, Berne RM (l980b) Brain adeno sine production in rat during sustained alteration in systemic blood pressure. Am J PhysioI239:H636-H641 Winn HR, Ru bio GR, Berne RM (1981a) The role of adenosine in the regulation of cerebral blood flow. J Cereb Blood Flow Metab 1:239-244 Winn HR, Ru bio R, Berne RM (1981b) Brain adenosine concen tration during hypoxia in rats. Am J Physiol 241:H235-H242
It has been hypothesized that calcium antago nists may be of significant benefit in the treatment of cerebral trauma, focal brain ischemia, and vaso spasm (Baethmann and Jansen, 1986) . The effects of the 1,4-dihydropyridine calcium antagonist ni fedipine have been extensively studied in both the coronary and the cerebral circulations. Nifedipine has been reported to reverse cerebral vasospasm following experimental subarachnoid hemorrhage (Allen and Bahr, 1979; Brandt et al., 1980) , to pre vent or diminish postischemic vasoconstriction, and to protect the brain during ischemia and hyp oxia (Brandt et al., 1983; Proctor et al., 1984; Wau quier et al., 1985) . The beneficial effects of nifed ipine on the ischemic heart have been attributed to several mechanisms, including dilation of the coro nary vessels and decreased myocardial oxygen re quirements as a result of the reduction in contrac tile behavior due to lessened Ca 2 + influx (Henry, 1980; Dejong et al., 1982) . Felodipine is a newer dihydropyridine derivative that, like nifedipine, in hibits vascular smooth muscle contraction by inter fering with calcium movements (Nyborg and Mul vany, 1984) . of adenosine and inosine. An inhibition of the transporter that mediates purine efflux from brain cells is likely to account for the suppression of release from the cerebral cortex. A reduced release of adenosine into the intersti tial space also explains the ability of both agents to block the increase in CBF evoked by hypoxic challenges. Key Words: Adenosine-Cerebral cortex-Felodipine Hypoxia-Inosine-Nifedipine.
Our initial interest in these compounds arose from the observation that nifedipine is a potent in hibitor of adenosine uptake by rat cerebral synap tosomes (Phillis et al., 1984b) . Since adenosine de presses calcium fluxes into synaptosomes (Wu et al., 1982) , the possibility arose that some of the Ca 2 + -antagonistic effects of nifedipine might be due to the potentiation of endogenously released aden osine. Studies on CBF had implicated adenosine in the generation of the cerebral reactive hyperemia that occurs during and after cerebral ischemia (Berne et al., 1983; Phillis et al., 1984a Phillis et al., , 1985a . In the expectation that nifedipine (and felodipine) would enhance hypoxia-induced CBFs, they were tested with a rat CBF model in use in this labora tory (Phillis et al., 1986) . In contrast to the antici pated results, nifedipine and felodipine (0.5 and 1 mg/kg, respectively) were observed to profoundly attenuate the increase in CBF produced by a brief period of anoxia. This action was tentatively attrib uted to an inhibitory action of the dihydropyridines on the "transporter" system that mediates the fa cilitated diffusion of adenosine across cell mem branes. The transporter mediates adenosine efflux as well as its uptake, and inhibition of the trans porter could result in a reduction of hypoxia-in duced adenosine release and a failure of the hyp oxia-induced vasodilation. The purpose of the present experiments was to substantiate this hy pothesis by measuring the actual release of adeno sine, and its metabolite inosine, from the rat cere bral cortex during experimentally induced hypoxia in the presence or absence of these dihydropyridine calcium antagonists. The results demonstrate that nifedipine and felodipine can attenuate adenosine and inosine efflux from the rat cerebral cortex.
METHODS

Animal preparation
Adult male Sprague-Dawley rats weighing 350-500 g were anesthetized with halothane. After tracheal cannu lation, anesthesia was maintained with methoxyflurane in air. Body temperature was maintained at 37°C with a heating pad controlled by a rectal probe. One femoral ar tery was cannulated for measurement of arterial blood pressure (Statham pressure transducer) and the with drawal of arterial blood samples for blood gas and pH analysis.
Animals were then placed in a stereotaxic instrument and the dorsal and dorsolateral surfaces of both cerebral hemispheres were exposed by careful removal of the overlying frontal and parietal bones. A thin strip of bone was left intact along the midline to protect the dorsal sag ittal venous sinus. The dura mater-arachnoid membrane complex overlying both hemispheres was carefully in cised and reflected to expose the brain. Complete hemo stasis was essential to prevent contamination of the arti ficial CSF with red blood cells and platelets, which are capable of releasing adenine nucleotides and adenosine in sufficient amounts to affect estimates of adenosine and inosine in perfusates (German and Kredich, 1984) . Rect angular cortical cups suspended in flexible mounting brackets (Phillis et aI., 1987) were then lowered onto both cortices, so that the frontal, parietal, and occipital cor tical surfaces were exposed within the cups. Each cup was then filled with an artificial CSF solution to ensure that there was no leakage of fluid. The dorsal surface of the head was covered with a mixture of 4% agar in artifi cial CSF to stabilize the cups and protect the exposed tissue from drying. The artificial CSF consisted of Na + 155.8 mEq/L, K+ 2.95 mEq/L, Ca 2 + 2.5 mEq/L, Mg 2 + 1.85 mEq/L, Cl-141.13 mEq/L, HC03 -22 mEq/L, dex trose 66.5 mg/dl, and urea 40.2 mg/di. The osmolarity of this solution was 302 mOsmol/L. The fluid was equili brated with 5% CO 2 and warmed to 37°C.
Experimental protocol
In each experiment the animal was subjected to a series of challenges during which it inhaled an 8% oxygen in nitrogen gas mixture for 10 min. A fixed schedule was followed in all experiments. One hundred fifty microliters of artificial CSF was placed in each cup for 10 min. At the expiration of the collection period, this fluid was with drawn with a Pasteur pipette and replaced with another 150-fJ.. l aliquot. The collected fluid was ejected into a chilled microvial inserted into an ice container and stored until assayed for adenosine and inosine. After one or two control collections, the animal was exposed to the 8% oxygen mixture for 10 min and the perfusate collected. The cups were refilled immediately and two further col lections were obtained during normoxic gas mixture in-J Cereb Blood Flow Metab, Vol. 8, No.2, 1988 halation. Nifedipine or felodipine was administered intra peritoneally at this point and a 15-min interruption of the collection sequence was scheduled to allow for absorp tion. Following a 10-min basal release collection, the an imal was exposed to a second lO-min hypoxic challenge, three normoxic collection periods, and a third hypoxic challenge; the experiment was terminated after two fur ther normoxic collection periods. To eliminate delays in the onset of hypoxia or anoxia, two identical British Ox ygen Corporation vaporizers were used for methoxy flurane and gas mixture administration. The 8% oxygen mixture in nitrogen was flushed through the second va porizer for several minutes prior to connection to the an imal, so that the onset of hypoxia was immediate.
Seven rats that received an intraperitoneal injection of saline were used for control studies to establish the repro ducibility of the purine releases evoked by the hypoxic challenges. Five rats received nifedipine (l mg/kg; Sigma) and five rats were administered felodipine (l mg/kg; A. B. Hassle); both dissolved in 0.2 ml of a mixture of dimethylsulfoxide and 0.9% NaCI solution (50:50, vol/ vol) (Phillis et aI., 1986).
HPLC procedures
The perfusate samples were centrifuged (5 min, 1,200 g 4°C) and the resulting supernates were analyzed for adenosine and inosine using HPLC. The chromato graphic system consisted of a Waters Associates M600A pump, U6K injector, in-line filter and precolumn, RCM-lOO radial compression module with Resolve 5-fJ.. m CI8 stationary phase, 450 variable-wavelength absor bance detector, and a Spectra-Physics 4270 integrator.
The chromatographic analysis was performed isocrat ically using a moving phase composition of 0.22 M (pH 6.8) phosphate buffer with 7% methanol (vol/vol) as or ganic modifier and 2.5 mM tetrabutylammonium phos phate as paired-ion chromatography reagent (Waters PIC-A).
The postcolumn effluent stream was monitored for chromatographic peaks at an absorption wavelength of 260 nm. Peaks were identified and quantified by com paring retention times, peak heights, and areas with those of known standards. Minimal detectable levels of adeno sine and inosine were 1 and 2 pmol, respectively, which, with a 100-fJ.. l injection volume of perfusate, corre sponded to 10 nM adenosine and 20 nM inosine concen trations.
The data in Ta bles 1 and 2 are presented as means ::t SEM. A paired t test was used to make statistical com parisons of the mean values of different conditions within the same groups of animals. A p value of <0.05 was ac cepted as indicating statistically significant differences.
RESULTS
Adenosine and inosine levels in the cortical per fusates reach stable levels by 10 min of incubation, and longer periods of exposure of the perfusate do not result in further increases in purine levels (Phillis et aI., 1988) . The cortical perfusate concen trations of adenosine and inosine fluctuated slightly from animal to animal. Mean basal levels of adeno sine in control samples collected from the three groups of animals ranged from 15.8 ± 2.3 to 33.8 ± Values are means ± SEM, expressed as nM. Perfusate collection periods were of IO-min duration. Hypoxic challenges (8% O 2 in inspired air) were of IO-min duration.
Significance values for increases in hypoxia-induced purine release in comparison with normoxic controls: ap < 0.01; b p < 0.001; cp < 0.05; dp < 0.02.
Significance values for reductions in basal or hypoxia-induced purine release following drug administration in comparison with pre drug controls: ep < O.OI;fp < 0.05; gp < 0.005. (Table 1) . Inosine levels were higher, ranging from means of 143.5 ± 17.2 to 378.9 ± 100.7 nM. Adenosine levels remained constant throughout the experiments in the animals of the control saline series (Table 1) , whereas the inosine levels declined slightly, but non significantly.
nM
The effects of a series of three identical reduc tions in the inspired oxygen to 8% on adenosine and inosine release were measured in seven an imals (14 cortical cups). One effect of a 10-min 8% hypoxic challenge was to cause a fall in MABP ( Table 2 ) that was rather pronounced in the first, but less so in the subsequent, challenges. Arterial pH levels become more alkaline (Table 2) , and Paco2 and Pao2 levels declined. The effects of the repeated challenges on pH, Paco2, and Pao2 were comparable. Adenosine and inosine releases were elevated during the hypoxic challenges (Table 1) and returned to control levels during the following two collection periods. The increases in adenosine release were reproducible in all three challenges and achieved significance for each challenge. The increases in inosine release were also significantly above basal for all three challenges, but it was no ticeable that the inosine levels collected during the third hypoxic challenge were significantly lower than those observed during the initial challenge. This decline was reflected in all of the animals in the series.
Nifedipine (1 mg/kg i.p.) was administered to five animals. Basal (normoxic) levels of adenosine re lease were not affected by nifedipine. The de-creases in basal inosine release, although achieving significance at the time of the third challenge, were similar to those in the control series of animals. Ni fedipine suppression of hypoxia-elicited adenosine release was apparent in the first postdrug chal lenge, and was very pronounced during the second challenge, at which time the release was essentially no different from that during the preceding nor moxic control period. A similar sequence of changes was observed in the inosine releases. During the first postdrug challenge, inosine release was increased over basal levels, but the increase was significantly less than that in the pre drug chal lenge or for the equivalent challenge period in the control animal series. Inosine release failed to in crease during the second postdrug challenge.
Four of the animals that had received nifedipine were maintained for 4 h after drug administration and then retested for basal and hypoxia-evoked adenosine and inosine release. The adenosine con tent of the eight cups during basal conditions (nor moxia) was 31.9 ± 6.6 nM and this increased to 65.6 ± 19.2 nM during the hypoxic challenge (p > 0.05). Basal inosine release was 153.4 nM and during the hypoxic challenge cup concentration was increased to 486.3 ± 142.0 nM (p < 0.05). Some recovery from the effects of the drug was therefore apparent.
Felodipine (1 mg/kg i.p.) was administered to five animals. Basal adenosine release was depressed in the collection period before the second postdrug challenge; basal inosine release was also reduced, but not significantly. Felodipine was even more ef fective than nifedipine, blocking the hypoxia-in duced release of adenosine and inosine in both the first and the second postdrug challenge periods.
The blood pressure, pH, and blood gas data for the animals in these experiments are presented in Table 2 . The fall in Paco2 values during the hypoxic challenges may have contributed to the severity of brain oxygen depletion. Hypocarbia is known to result in cerebral vasoconstriction, and the ensuing reduction in oxygen availability can lead to in creased cerebral adenosine levels (Winn et aI., 198 1b) . Although both nifedipine and felodipine slightly reduced MABP, these effects were not sig nificant; nor were the falls in MABP recorded during successive hypoxic challenges affected by either agent. Similarly neither compound altered the blood pH, Paco2, and Pao2 values recorded under normoxic or hypoxic conditions.
DISCUSSION
The present data show that nifedipine and felodi pine significantly reduced the hypoxia-induced re-J Cereb Blood Flow Metab, Vol. 8, No.2, 1988 lease of adenosine and inosine into rat cerebral cor tical collecting cups. Nifedipine administration re sulted in a decrease in the basal release of inosine, but not adenosine, under normoxic conditions, and felodipine caused a decrease in the basal release of both adenosine and inosine, although this reduction achieved significance only for adenosine. The failure of hypoxic challenges to release adenosine after 1,4-dihydropyridine administration offers an explanation for our previous observation that nifed ipine and felodipine (0.5 and 1 mg/kg i.p., respec tively) depress the increase in rat CBF elicited by brief anoxic challenges (Phillis et aI., 1986). Adeno sine has been proposed as a regulator of CBF during hypoxia (Berne et aI., 1974; Winn et aI., 198 1a; Phillis et aI., 1984a Phillis et aI., , 1985a . Adenosine is a potent cerebral vasodilator (Berne et aI., 1974; Wahl and Kuschinsky, 1976; Morii et aI., 1986) and it is produced in the brain during hypoxia, isch emia, and seizures (Berne et aI., 1974; Winn et aI., 1979 Winn et aI., , 1980a . In addition, increases in CSF and brain interstitial fluid adenosine concentrations have been documented during hypoxia and isch-emia (Berne et ai., 1974; Zetterstrom et ai., 1982; Van Wylen et ai., 1986; Park et ai., 1987; Phillis et aI., 1988) . Inhibition of adenosine release during hypoxic episodes provides an explanation for the ability of the 1 ,4-dihydropyridines to abolish the ce rebral reactive hyperemia in response to hypoxic challenges (Phillis et ai., 1986) .
A parallel situation apparently occurs in the dog coronary circulation where nifedipine has also been observed to attenuate the reactive hyperemia fol lowing coronary artery occlusion (Bache and To ckman, 1982; Merrill et aI., 1982) . Studies on the isolated rat heart have shown that nifedipine pre vents ischemia-induced release of adenosine and inosine into the coronary perfusate (DeJong et ai., 1982) . As adenosine has been implicated in the con trol of coronary vessel flow (Berne et ai., 1983), a failure of adenosine release would satisfactorily ac count for the attenuation of ischemia-induced coro nary reactive hyperemia by nifedipine. Human studies comparing the effects of flunarizine and ni fedipine on leg blood flow showed that nifedipine decreased, while flunarizine increased, postisch emic blood flow (DiPerri et ai., 1984) .
These results on the block of reactive hyperemias in various vascular beds could be interpreted as suggesting that nifedipine (and felodipine) act by antagonizing the action of adenosine, which is known to be released in increased quantities as the catabolic product of ATP hydrolysis. This idea de rives some support from experiments showing that nifedipine can displace the binding of the adenosine receptor ligands N6-cyclohexyladenosine and 1,3diethyl-8-phenylxanthine from brain membranes (Murphy and Snyder, 1982) . However, in studies on rat cerebral cortical neurons, iontophoretically ap plied nifedipine potentiated, rather than antago nized, the actions of adenosine (Phillis et aI., 1984b). Alternatively, nifedipine could inhibit the release of adenosine, thereby blunting its vasodila tory effects. Nifedipine has been demonstrated to inhibit the uptake of adenosine into brain synapto somes (Phillis et aI., 1984b), and it is likely that it alters the activity of the bidirectional transporter that mediates the facilitated diffusion of adenosine across cell membranes. This action has been attrib uted to nifedipine's ability to interfere with a cal modulin-like protein regulating the adenosine trans port process (Wu et ai., 1983; Phillis et ai., 1984b) or to a coupling of the dihydropyridine receptor site to the nucleoside transporter (Streissnig et aI., 1985) .
An ability of two adenosine transport inhibitors to attenuate the release of adenosine from hypoxic rat hepatocytes has been elegantly demonstrated (Belloni et aI., 1985) . At concentrations that re duced adenosine uptake by hepatocytes, dipyri damole and nitrobenzylthioinosine suppressed the release of the purine from hypoxic hepatocytes. It is reasonable to assume that nifedipine could also have similar effects on adenosine uptake and re lease from brain cells. The ability to inhibit adeno sine transport is shared by other 1,4-dihydropyri dines, including nimodipine (Streissnig et ai., 1985) , which has been extensively used in cerebral vas cular studies.
A third alternative, namely, that the 1,4-dihydro pyridines are having a depressant, stabilizing action on cerebral activity and thus reducing both ATP utilization and adenosine formation and release, is unlikely. At therapeutic doses, the 1,4-dihydropyri dines have minimal effect on behavioral functions (Swanson and Green, 1986) and do not alter cere bral metabolic rates (CMR0 2 or glucose utilization) (Mohamed et aI., 1985; Forsman et aI., 1986; Sa kabe et ai., 1986) .
Inhibition of adenosine release from hypoxic brain cells could account for the so-called "ATP sparing" action of the 1 ,4-dihydropyridines. Pre treatment with nimodipine temporarily retards the fall of ATP, but not of phosphocreatine, in the cortex and striatum of gerbils during ischemic epi sodes (Heffez and Passonneau, 1985) . 1,4-Dihydro pyridines may be able to promote ATP sparing by preventing the loss of adenosine from brain cells. More adenosine will thus be available for the re synthesis of ATP at the expense of the phospho creatine stores.
The present results indicate a need for caution in the therapeutic use of 1,4-dihydropyridines to alleviate the effects of cerebral vascular insuffi ciency and may shed some light on the conflicting claims that have been expressed in reports on the administration of these compounds in experimental ischemia. Clinical experience with nifedipine has shown that it may induce myocardial ischemia in patients with refractory angina pectoris (Jariwalla and Anderson, 1978; Stone et ai., 1983; Boden et aI., 1985) , an effect opposite to that expected of cal cium channel blockade. Although this finding has been attributed to a "coronary steal" phenomenon (Jariwalla and Anderson, 1978) , there is no experi mental evidence to support this conclusion. A re duction of adenosine release and failure of coro nary vasodilation could provide an equally plau sible explanation. There exists a similar possibility that a failure of adenosine-dependent autoregula tion following a 1,4-dihydropyridine calcium antag onist administration could further jeopardize the vi ability of "at risk" areas of the brain. Indeed, a se-vere impairment of CBF responses to arterial Pc0 2 changes and autoregulation to reduced blood pres sure following nimodipine administration has been observed in baboons (Harris et aI., 1982) . As cere bral vascular responses to both hypotension and hypercapnia may involve adenosine (Winn et aI., 1980b; Phillis and DeLong, 1987) , the failure of these responses following nimodipine administra tion might have been predicted.
In animal experiments, dihydropyridine calcium antagonists have been claimed to protect the brain during ischemia or hypoxia (Steen et aI., 1983; Wiernsperger et aI., 1984; Fujisawa et aI., 1986; Mabe et aI., 1986; Milde et aI., 1986) . The issue is controversial, however, in that some studies have failed to demonstrate beneficial effects of these drugs in brain ischemia (Barnett et aI., 1986; Gotoh et aI., 1986; Sakabe et aI., 1986; Vorstrup et aI., 1986) .
Insofar as their effects on adenosine release are considered, conflicting results might be anticipated with administration of the dihydropyridines. As summarized by Newby (1984), adenosine's physio logical function appears to be to allow a target cell to adjust its energy supply to its activity and to re taliate against external stimuli that would tend to cause excessive ATP breakdown. According to this concept, any failure of adenosine release into the interstitial space would jeopardize the cell's ability to match its activity to its energy supply, which during a state of circulatory insufficiency could be fatal to the cell.
Offsetting this potential disadvantage of the use of dihydropyridine calcium antagonists is the reten tion of adenosine within cells and their ATP-sparing action referred to above. Another consideration would be the production of oxygen-derived free radicals that may play a major role in ischemic and reperfusion injury (McCord, 1985) . The primary source of superoxide under these conditions ap pears to be the action of xanthine oxidase on the nucleoside catabolites hypoxanthine and xanthine. Because of the formation of adenosine during isch emia and its rapid deamination to inosine, higher amounts of substrates (hypoxanthine and xanthine) for xanthine oxidase should be available upon re perfusion. The subsequent massive formation of superoxide (and hydroxyl) radicals may then result in irreversible damage. By preventing the release of adenosine, and promoting its reincorporation into ATP, the cerebroprotective dihydropyridines may be able to decrease the rate of formation of oxygen radicals, thus enabling the local defense mecha nisms (dismutase, catalase) to successfully cope with this threat to cell viability. Belloni FL, Elkin PL, Gi anotto B (1985) The mechanism of adenosine release from hypoxic rat liver cells. Swanson TH, Green CL (1986) Nifedipine: more than a calcium channel blocker. Wauquier A, Ashton D, Clincke G, Fransen J (1985) "Calcium entry blockers" as cerebral protecting agents: comparative activity in test of hypoxia and hyperexcitability. Jpn J Phar macoI38:1-7
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